Logo image of SRXH

SRX HEALTH SOLUTIONS INC (SRXH) Stock Fundamental Analysis

NYSEARCA:SRXH - NYSE Arca - US08771Y4026 - Common Stock - Currency: USD

0.5511  -0.04 (-6.59%)

After market: 0.5579 +0.01 (+1.23%)

Fundamental Rating

3

Overall SRXH gets a fundamental rating of 3 out of 10. We evaluated SRXH against 91 industry peers in the Food Products industry. The financial health of SRXH is average, but there are quite some concerns on its profitability. SRXH is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year SRXH has reported negative net income.
In the past year SRXH has reported a negative cash flow from operations.
In the past 5 years SRXH reported 4 times negative net income.
In the past 5 years SRXH reported 4 times negative operating cash flow.
SRXH Yearly Net Income VS EBIT VS OCF VS FCFSRXH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

SRXH has a better Return On Assets (11.11%) than 93.48% of its industry peers.
SRXH has a Return On Equity of 21.33%. This is amongst the best in the industry. SRXH outperforms 91.30% of its industry peers.
Industry RankSector Rank
ROA 11.11%
ROE 21.33%
ROIC N/A
ROA(3y)-79.59%
ROA(5y)-70.15%
ROE(3y)-316.39%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SRXH Yearly ROA, ROE, ROICSRXH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

1.3 Margins

With a decent Profit Margin value of 4.96%, SRXH is doing good in the industry, outperforming 70.65% of the companies in the same industry.
With an excellent Gross Margin value of 37.27%, SRXH belongs to the best of the industry, outperforming 82.61% of the companies in the same industry.
SRXH's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 4.96%
GM 37.27%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.59%
GM growth 5Y-0.26%
SRXH Yearly Profit, Operating, Gross MarginsSRXH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K

More info and screens

5

2. Health

2.1 Basic Checks

SRXH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SRXH has been increased compared to 1 year ago.
SRXH has more shares outstanding than it did 5 years ago.
SRXH has a better debt/assets ratio than last year.
SRXH Yearly Shares OutstandingSRXH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
SRXH Yearly Total Debt VS Total AssetsSRXH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -27.19, we must say that SRXH is in the distress zone and has some risk of bankruptcy.
SRXH's Altman-Z score of -27.19 is on the low side compared to the rest of the industry. SRXH is outperformed by 92.39% of its industry peers.
There is no outstanding debt for SRXH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -27.19
ROIC/WACCN/A
WACC7.81%
SRXH Yearly LT Debt VS Equity VS FCFSRXH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

SRXH has a Current Ratio of 1.99. This is a normal value and indicates that SRXH is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of SRXH (1.99) is better than 64.13% of its industry peers.
SRXH has a Quick Ratio of 1.37. This is a normal value and indicates that SRXH is financially healthy and should not expect problems in meeting its short term obligations.
SRXH has a Quick ratio of 1.37. This is in the better half of the industry: SRXH outperforms 75.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.99
Quick Ratio 1.37
SRXH Yearly Current Assets VS Current LiabilitesSRXH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 107.92% over the past year.
SRXH shows a decrease in Revenue. In the last year, the revenue decreased by -8.12%.
SRXH shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.56% yearly.
EPS 1Y (TTM)107.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.73%
Revenue 1Y (TTM)-8.12%
Revenue growth 3Y-8.73%
Revenue growth 5Y17.56%
Sales Q2Q%-9.4%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y273.33%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year25%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SRXH Yearly Revenue VS EstimatesSRXH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M
SRXH Yearly EPS VS EstimatesSRXH Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 0 -10 -20 -30

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

SRXH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 2.08, the valuation of SRXH can be described as very cheap.
Based on the Price/Forward Earnings ratio, SRXH is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
SRXH is valuated cheaply when we compare the Price/Forward Earnings ratio to 35.19, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 2.08
SRXH Price Earnings VS Forward Price EarningsSRXH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SRXH Per share dataSRXH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

SRXH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SRX HEALTH SOLUTIONS INC

NYSEARCA:SRXH (7/11/2025, 8:04:01 PM)

After market: 0.5579 +0.01 (+1.23%)

0.5511

-0.04 (-6.59%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)08-11 2025-08-11
Inst Owners1.31%
Inst Owner ChangeN/A
Ins Owners8.55%
Ins Owner Change0%
Market Cap6.43M
Analysts82.86
Price Target10.2 (1750.84%)
Short Float %4.73%
Short Ratio0.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 2.08
P/S 0.19
P/FCF N/A
P/OCF N/A
P/B 0.81
P/tB 0.85
EV/EBITDA N/A
EPS(TTM)-2.43
EYN/A
EPS(NY)0.27
Fwd EY48.12%
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS2.93
BVpS0.68
TBVpS0.65
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 11.11%
ROE 21.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 4.96%
GM 37.27%
FCFM N/A
ROA(3y)-79.59%
ROA(5y)-70.15%
ROE(3y)-316.39%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.59%
GM growth 5Y-0.26%
F-Score5
Asset Turnover2.24
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 37.19%
Cap/Sales 0.13%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.99
Quick Ratio 1.37
Altman-Z -27.19
F-Score5
WACC7.81%
ROIC/WACCN/A
Cap/Depr(3y)14.78%
Cap/Depr(5y)14.84%
Cap/Sales(3y)0.18%
Cap/Sales(5y)0.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)107.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.73%
EPS Next Y273.33%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-8.12%
Revenue growth 3Y-8.73%
Revenue growth 5Y17.56%
Sales Q2Q%-9.4%
Revenue Next Year25%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y61.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year147.5%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y79.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y79.34%
OCF growth 3YN/A
OCF growth 5YN/A